Idiopathic pulmonary fibrosis: current and future directions

Clinical Radiology

Volumn 72, Issue 5, 2017, Pages 343-355

  Soo, E ^a   Adamali, H ^a   Edey, A J ^a  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; PIRFENIDONE;

ALLERGIC PNEUMONITIS; ARTICLE; DISEASE EXACERBATION; EARLY DIAGNOSIS; EMPHYSEMA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HISTOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG CANCER; LUNG TRANSPLANTATION; LYMPHADENOPATHY; META ANALYSIS (TOPIC); MULTIDETECTOR COMPUTED TOMOGRAPHY; PLEURA THICKENING; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW (TOPIC); DIAGNOSTIC IMAGING; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PROCEDURES; TRENDS; X-RAY COMPUTED TOMOGRAPHY;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85009964688     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2016.12.014     Document Type: Article

References (108)

1. 1 Navaratnam, V., Fleming, K.M., West, J., et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 66 (2011), 462–467.
2. 2 Spiteri, M., The British Thoracic Society Interstitial Lung Disease Registry Programme Annual Report 2014/15. British Thoracic Society Reports, 7(1), 2015.
3. 3 Lamas, D.J., Kawut, S.M., Bagiella, S., et al. Delayed access and survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 842–847.
4. 4 Kim, D.S., Collard, H.R., King, T.E. Jr, Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3 (2006), 285–292.
5. 5 British Thoracic Society Standards of Care Committee, The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 54 (1999), S1–S30.
6. 6 American Thoracic Society (ATS), European Respiratory Society (ERS), American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161 (2000), 646–664.
7. 7 Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu, G., Anstrom, K.J., King, T.E. Jr., et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366 (2012), 1968–1977.
8. 8 Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
9. 9 Silva, C.I., Mueller, N.L., Lynch, D.A., et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 246 (2008), 288–297.
10. 10 King, T.E. Jr., Pardo, A., Selman, M., Idiopathic pulmonary fibrosis. Lancet 378 (2011), 1949–1961.
11. 11 Baumgartner, K.B., Samet, J.M., Stidley, C.A., et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155 (1997), 242–248.
12. 12 Iwai, K., Mori, T., Yamada, N., et al. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 150 (1994), 670–675.
13. 13 Ekström, M., Gustafson, T., Boman, K., et al. Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case–control study. BMJ Open, 4, 2014.
14. 14 Lawson, W.E., Loyd, J.E., The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease?. Proc Am Thorac Soc 3 (2006), 345–349.
15. 15 Hodgson, U., Laitinen, T., Tukiainen, P., Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 57 (2002), 338–342.
16. 16 Armanios, M.Y., Chen, J.J., Cogan, J.D., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356 (2007), 1317–1326.
17. 17 Wang, Y., Kuan, P.J., Xing, C., et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 84 (2009), 52–59.
18. 18 Stella, G.M., Balestro, E., Lacedonia, D., et al. Telomeropathies: an emerging spectrum of disorders with important implications for patients with interstitial lung disease. Minerva Med 107:Suppl 1 (2016), 9–14.
19. 19 Sverzellati, N., Highlights of HRCT imaging in IPF. Respir Res, 14(Suppl. 1), 2013, S3.
20. 20 Kuhn, C. 3rd, Boldt, J., King, T.E. Jr., et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 140 (1989), 1693–1703.
21. 21 King, T.E. Jr., Schwarz, M.I., Brown, K., et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 164 (2001), 1025–1032.
22. 22 Tiitto, L., Bloigu, R., Heiskanen, U., et al. Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 61 (2006), 1091–1095.
23. 23 King, T.E. Jr., Tooze, J.A., Schwarz, M.I., et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164 (2001), 1171–1181.
24. 24 Nicholson, A.G., Fulford, L.G., Colby, T.V., et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 166 (2002), 173–177.
25. 25 Flaherty, K.R., Andrei, A.C., King, T.E. Jr., et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. Am J Respir Crit Care Med 175 (2007), 1054–1060.
26. 26 Thomeer, M., Demedts, M., Behr, J., et al. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 31 (2008), 585–591.
27. 27 Nicholson, A.G., Addis, B.J., Bharucha, H., et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 59 (2004), 500–505.
28. 28 Lettieri, C.J., Veerappan, G.R., Parker, J.M., et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med 99 (2005), 1425–1430.
29. 29 Flaherty, K.R., Travis, W.D., Colby, T.V., et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 164 (2001), 1722–1727.
30. 30 Visscher, D.W., Myers, J.L., Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 3 (2006), 322–329.
31. 31 Yagihashi, K., Huckleberry, J., Colby, T.V., et al. Radiologic–pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J 47 (2016), 1189–1197.
32. 32 Flaherty, K.R., Thwaite, E.L., Kazerooni, E.A., et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 58 (2003), 143–148.
33. 33 Kaarteenaho, R., The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Respir Res, 14, 2013, 43.
34. 34 Hansell, D.M., Bankier, A.A., MacMahon, H., et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 246 (2008), 697–722.
35. 35 Silva, C.I., Mueller, N.L., Hansell, D.M., et al. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 247 (2008), 251–259.
36. 36 Elliot, T.L., Lynch, D.A., Newell, J.D., High-resolution computed tomography features of nonspecific interstitial pneumonia and usual interstitial pneumonia. J Comput Assist Tomogr 29 (2005), 339–345.
37. 37 Chung, J.H., Chawla, A., Peljto, A.L., et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest 147 (2015), 450–459.
38. 38 Watadani, T., Sakai, F., Johkoh, T., et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 266 (2013), 936–944.
39. 39 Johkoh, T., Sakai, F., Noma, S., et al. Honeycombing on CT: its definitions, pathologic correlation, and future direction of its diagnosis. Eur J Radiol 83 (2014), 27–31.
40. 40 Lee, H.Y., Lee, K.S., Jeong, Y.J., et al. High-resolution CT findings in fibrotic idiopathic interstitial pneumonias with little honeycombing: serial changes and prognostic implications. AJR Am J Roentgenol 199 (2012), 982–989.
41. 41 Walsh, S.L., Calandriello, L., Sverzellati, N, et al. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 71 (2016), 45–51.
42. 42 Lynch, D.A., Travis, W.D., Muller, N.L., et al. Idiopathic interstitial pneumonias: CT features. Radiology 236 (2005), 10–21.
43. 43 Edey, A.J., Devaraj, A.A., Barker, R.P., et al. Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol 21 (2011), 1586–1593.
44. 44 Cottin, V., Richeldi, L., Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev 23 (2014), 106–110.
45. 45 Gruden, J.F., CT in idiopathic pulmonary fibrosis: diagnosis and beyond. AJR Am J Roentgenol 206 (2016), 495–507.
46. 46 Wells, A.U., Desai, S.R., Rubens, M.B., et al. Idiopathic pulmonaryfibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167 (2003), 962–969.
47. 47 Jo, H.E., Corte, T.J., Wort, S.J., et al. Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease. Respirology 21 (2016), 556–566.
48. 48 Fell, C.D., Martinez, F.J., Liu, L.X., et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 181 (2010), 832–837.
49. 49 Raghu, G., Wells, A.U., Nicholson, A.G., et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med, 2016 Jun 22.
50. 50 Ryerson, C.J., Hartman, T., Elicker, B.M., et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 144 (2013), 234–240.
51. 51 Gruden, J.F., Panse, P.M., Leslie, K.O., et al. UIP diagnosed at surgical lung biopsy, 2000–2009: HRCT patterns and proposed classification system. AJR Am J Roentgenol, 200, 2013.
52. 52 Gruden, J.F., Panse, P.M., Gotway, M., et al. Diagnosis of usual interstitial pneumonitis in the absence of honeycombing: evaluation of specific CT criteria with clinical follow-up in 38 patients. AJR Am J Roentgenol 206 (2016), 472–480.
53. 53 Hunninghake, G.W., Lynch, D.A., Galvin, J.R., et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 124 (2003), 1215–1223.
54. 54 Souza, C.A., Müller, N.L., Lee, K.S., et al. Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients. AJR Am J Roentgenol 186 (2006), 995–999.
55. 55 Raghu, G., Amatto, V.C., Behr, J., et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 46 (2015), 1113–1130.
56. 56 Raghu, G., Freudenberger, T., Yang, S., et al. High prevalence of abnormal acid reflux in idiopathic pulmonary fibrosis. Eur Respir J 27 (2006), 136–142.
57. 57 Lee, J.S., Collard, H.R., Anstrom, K.J., et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1 (2013), 369–376.
58. 58 Schachter, L.M., Dixon, J., Pierce, R.J., et al. Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest 123 (2003), 1932–1938.
59. 59 Shorr, A., Wainright, J., Cors, C., et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J, 30, 2007 715–721.59.
60. 60 Shin, S., King, C.S., Puri, N., et al. Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J 47 (2016), 1445–1451.
61. 61 Watanabe, A., Miyajima, M., Mishina, T., et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg 61 (2013), 254–261.
62. 62 Kishi, K., Homma, S., Kurosaki, A., et al. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr 30 (2006), 95–99.
63. 63 Park, J., Kim, D.S., Shim, T.S., et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17 (2001), 1216–1219.
64. 64 Khan, K.A., Kennedy, M.P., Moore, E., et al. Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung 193 (2015), 71–77.
65. 65 Lee, T., Park, J., Lee, H., et al. Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med 108 (2014), 1549–1555.
66. 66 Kushibe, K., Kawaguchi, T., Takahama, M., et al. Operative indications for lung cancer with idiopathic pulmonary fibrosis. Thorac Cardiovasc Surg 55 (2007), 505–508.
67. 67 Watanabe, A., Higami, T., Ohori, S., et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?. J Thorac Cardiovasc Surg 136 (2008), 1357–1363.
68. 68 Kawasaki, H., Nagai, K., Yoshida, J., et al. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol 81 (2002), 33–37.
69. 69 Fujimoto, T., Okazaki, T., Matsukura, T., et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?. Ann Thorac Surg 76 (2003), 1674–1678 discussion 1679.
70. 70 Kumar, P., Goldstraw, P., Yamada, K., et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 125 (2003), 1321–1327.
71. 71 Tomassetti, S., Gurioli, C., Ryu, J., et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 147 (2015), 157–164.
72. 72 Silva, C., Müller, N.L., Idiopathic interstitial pneumonias. Thorac Imaging 24 (2009), 260–273.
73. 73 Song, J.W., Hong, S.B., Lim, C.M., et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37 (2011), 356–363.
74. 74 Collard, H.R., Yow, E., Richeldi, L., et al., investigators IP. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res, 14, 2013, 73.
75. 75 Collard, R., Ryerson, C.J., Tamera, J., et al. Acute exacerbation of idiopathic pulmonary fibrosis: an International Working Group Report AJRCCM., June 2016.
76. 76 Flaherty, K.R., King, T.E. Jr., Raghu, G., et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med 170 (2004), 904–910.
77. 77 Walsh, S.L., Wells, A.U., Desai, S.R., et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case–cohort study. Lancet Respir Med, 2016 S2213–2600(16)30033-9.
78. 78 Jin, G.Y., Lynch, D., Chawla, A., et al. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 268 (2013), 563–571.
79. 79 Lynch, D.A., Lung disease related to collagen vascular disease. J Thorac Imaging 24 (2009), 299–309.
80. 80 Fischer, A., Antoniou, K.M., Brown, K.K., et al. ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46 (2015), 976–998.
81. 81 King, T.E., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
82. 82 Noble, P.W., Albera, C., Bradford, W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
83. 83 Richeldi, L., duBois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
84. 84 NICE. Pirfenidone for treating idiopathic pulmonary fibrosis, NICE technology appraisal guidance [TA282] 24 April 2013.
85. 85 Aravena, C., Labarca, G., Venegas, C., et al. Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One, 10, 2015, e0136160.
86. 86 Nathan, S.D., Albera, C., Bradford, W.Z., et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 71 (2016), 429–435.
87. 87 Wuyts, WA, Kolb, M., Stowasser, S., et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of 50% of predicted value. Lung 194 (2016), 739–743.
88. 88 King, C.S., Nathan, S.D., Should all patients with IPF, even those with more than moderate impairment, be treated with nintedanib or pirfenidone?: Yes. Chest 150 (2016), 273–275.
89. 89 Yusen, R.D., Edwards, L.B., Kucheryavaya, A.Y., et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart–lung transplant report—2014: focus theme: retransplantation. J. Heart Lung Transplant 33 (2014), 1009–1024.
90. 90 Thabut, G., Mal, H., Castier, Y., et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 126 (2003), 469–475.
91. 91 Bennett, D., Fossi, A., Bargagli, E., et al. Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience. Lung 193 (2015 Oct), 677–681.
92. 92 Kilic, A., Merlo, C.A., Conte, J.V., et al. Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score?. J Thorac Cardiovasc Surg 144 (2012), 1133–1138.
93. 93 Kitaguchi, Y., Fujimoto, K., Hanaoka, M., et al. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 15:2 (2010), 265–271.
94. 94 Lauretis, A.D., Basara, H., Hakwin, W., et al. PPFE predicts survival in IPF. Am J Respir Crit Care Med, 193, 2016, A1142.
95. 95 du Bois, R.M., Weycker, D., Albera, C., et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 459–466.
96. 96 du Bois, R.M., Weycker, D., Albera, C., et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 184 (2011), 1382–1389.
97. 97 du Bois, R.M., Weycker, D., Albera, C., et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183 (2011), 1231–1237.
98. 98 Ley, B., Ryerson, C.J., Vittinghoff, E., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156 (2012), 684–691.
99. 99 Ley, B., Elicker, B.M., Hartman, T.E., et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology 273 (2014), 570–579.
100. 100 Walsh, S., Sverzellati, N., Devaraj, A., et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 69 (2014), 216–222.
101. 101 Oda, K., Ishimoto, H., Yatera, K., et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res, 15, 2014, 10.
102. 102 Romei, C., Tavanti, L., Sbragia, P., et al. Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ERS/JRS/ALAT in 2011 predict disease progression and prognosis?. Radiol Med 120 (2015), 930–940.
103. 103 Kim, Y.S., Jin, G.Y., Chae, K.J., et al. Visually stratified CT honeycombing as a survival predictor in combined pulmonary fibrosis and emphysema. Br J Radiol, 88, 2015, 20150545.
104. 104 Shin, K.M., Lee, K.S., Chung, M.P., et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology 249 (2008 Oct), 328–337.
105. 105 Iwasawa, T., Kanauchi, T., Hoshi, T., et al. Multicenter study of quantitative computed tomography analysis using a computer-aided three-dimensional system in patients with idiopathic pulmonary fibrosis. Jpn J Radiol 34 (2016), 16–27.
106. 106 Alemzadeh, M., Boylan, C., Kamath, M.V., Review of texture quantification of CT images for classification of lung diseases. Crit Rev Biomed Eng 43 (2015), 183–200.
107. 107 Jacob, J., Bartholmai, B.J., Rajagopalan, S., et al. Automated quantitative computed tomography versus visual computed tomography scoring in idiopathic pulmonary fibrosis: validation against pulmonary function. J Thorac Imaging 31 (2016), 304–311.
108. 108 Kim, H.J., Brown, M.S., Chong, D., et al. Comparison of the quantitative CT imaging biomarkers of idiopathic pulmonary fibrosis at baseline and early change with an interval of 7 months. Acad Radiol 22:1 (2015 Jan), 70–80.